Zoom Leads A Workplace Revolution
December 10, 2025
Zoom Leads A Workplace Revolution Leave a reply Major new brand campaign developed with Colin Jost’s No Notes Productions lampoons bad tech and champions the
Press Releases
One New Star Shines in the MICHELIN Guide Doha’s Second Edition
December 10, 2025
Group Photo MICHELIN Guide unveils its 2026 edition the second since its debut last year at the St. Regis Doha 1 restaurant is promoted to
One New Star Shines in the MICHELIN Guide Doha’s Second Edition
December 10, 2025
Group Photo 1 restaurant is promoted to One MICHELIN Star, while 2 others retain their Stars 4 new Bib Gourmand distinctions added, bringing the total
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy
December 8, 2025
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec.
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy
December 8, 2025
RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
December 8, 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
December 8, 2025
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
December 8, 2025
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH)
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
December 8, 2025
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated